EN DE
Watch NervGen Pharma Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

NervGen Pharma Corp (NGEN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of NervGen Pharma Corp stock $0.63, price $1.33, that is 52.6% below the price, quality 35 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Canada · ISIN CA64082X2032

NP NervGen Pharma Corp logo Thin data Nov 10, 2026

NervGen Pharma Corp

NGEN · US
Very expensive, weak quality

Our calculation puts a fair price 53% below what the stock costs today.

Fair value $0.6300 · Strongly overvalued
Quality 35/100
Negative free cash flow
Trails peers (2/7)
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch NervGen Pharma Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$5.97 $1.12 Fair Value $0.6300 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.12 – $5.97 · fair‑value band $0.4700 – $0.7800 · the $1.33 price screens above the $0.6300 fair value. As of Nov 10, 2026.

Follow NervGen Pharma in your weekly email

Every Wednesday you see whether NervGen Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.

Show moreShow less

The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.

NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.

NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Stock analysis

NervGen Pharma Corp (NGEN) currently trades at $1.33, while our estimate is $0.6300, 53% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.4700 (bear) to $0.7800 (bull), the price of $1.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

NervGen Pharma Corp reported revenue of C$0 in FY2025 versus C$0 in FY2022. Reported net income was −C$44.1M in FY2025.

Key figures

Market cap $155M Micro · EPS (TTM) $−0.5700 · Return on equity −96.8% · Return on assets (EBIT) −108% (5-year average) · Free cash flow −$19.5M · Net cash $22.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 78% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −53%, NGEN screens richer than that median.

Fair Value

Bear $0.4700 Fair Value $0.6300 Bull $0.7800
Price $1.33 · Downside -52.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 38
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NGEN screens overvalued: fair value 53% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare NervGen Pharma Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −52.6% · Bottom 25%
Profitability
Return on assets −190.1% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 44.53× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs NGEN
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs NGEN
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs NGEN
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs NGEN
argenx SE ARGX $971.55 $908.40 −7% vs NGEN
CSL Limited CSL A$201.68 A$181.40 −10% vs NGEN
Moderna, Inc MRNA $250.83 $158.70 −37% vs NGEN
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs NGEN
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs NGEN
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs NGEN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NervGen Pharma Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NervGen Pharma Corp Fair Value". https://www.fairvalue-calculator.com/stock/NGEN

Frequently asked questions

Is NervGen Pharma Corp (NGEN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.6300 versus a price of $1.33, about 53% lower (overvalued).
What is the fair value of NGEN?
Our estimate for NervGen Pharma Corp is $0.6300 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.33.
What is the quality score of NGEN?
NervGen Pharma Corp has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NervGen Pharma Corp (NGEN)?
Our calculated price target is the estimate of $0.6300 (as of Nov 10, 2026). Cautious scenario $0.4700, optimistic scenario $0.7800. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the NervGen Pharma Corp stock forecast for 2026?
Our estimate puts fair value at $0.6300, about 53% lower versus a price of $1.33 (overvalued). Cautious scenario $0.4700, optimistic scenario $0.7800. The calculation is refreshed regularly with new filings.
What is the intrinsic value of NervGen Pharma Corp (NGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NervGen Pharma Corp it is $0.6300 per share (as of Nov 10, 2026), against a price of $1.33.
Is NervGen Pharma Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, NGEN trades above its calculated fair value: price $1.33, fair value $0.6300, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NGEN?
No. The price is what the market pays today ($1.33); the fair value is what the company's own numbers justify ($0.6300). For NervGen Pharma Corp the two are $0.7000 per share apart. That gap is exactly why we show both numbers side by side.
How much is NervGen Pharma Corp worth?
The market values NervGen Pharma Corp at about $155M (market capitalisation, as of Nov 10, 2026). Per share that is $1.33; our models calculate a fair value of $0.6300 per share.
What do the bullish and bearish scenarios say about NGEN?
Our models span a range for NervGen Pharma Corp: cautious scenario $0.4700, base $0.6300, optimistic $0.7800 per share (as of Nov 10, 2026, price $1.33). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NervGen Pharma Corp (NGEN)?
Balance-sheet figures for NervGen Pharma Corp (as of Nov 10, 2026): return on equity −96.8%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is NGEN from its 52-week high?
NervGen Pharma Corp trades at $1.33, about 78% below its 52-week high of $5.97 and 1% above the low of $1.32 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6300 is for.
Which stocks are comparable to NervGen Pharma Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NervGen Pharma Corp stock attractive at the current price?
The data as of Nov 10, 2026: price $1.33, calculated fair value $0.6300 (−53%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. NervGen Pharma Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NervGen Pharma Corp (NGEN)?
The closing price on Nov 10, 2026 was $1.33. Our estimate is $0.6300, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NervGen Pharma Corp right now?
The price sits above even our optimistic bull case ($0.7800). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of NervGen Pharma Corp

How large is the market capitalisation of NervGen Pharma Corp (NGEN)?
The market capitalisation of NervGen Pharma Corp is $155M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of NervGen Pharma Corp (NGEN)?
Earnings per share at NervGen Pharma Corp are $−0.5700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of NervGen Pharma Corp (NGEN)?
The return on equity (ROE) of NervGen Pharma Corp is −96.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NervGen Pharma Corp (NGEN)?
On an EBIT basis the return on assets of NervGen Pharma Corp is −108% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does NervGen Pharma Corp (NGEN) generate?
The free cash flow of NervGen Pharma Corp is −$19.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does NervGen Pharma Corp (NGEN) hold?
NervGen Pharma Corp holds more cash than debt, $22.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch NervGen Pharma Corp in the live analysis

One click puts NervGen Pharma Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.